BRPI0821855A2 - Composto, agente farmacêutico, uso de um composto inibidor de dna girase bacteriana, agente antibacteriano, e, agente terapêutico para doença infecciosa - Google Patents

Composto, agente farmacêutico, uso de um composto inibidor de dna girase bacteriana, agente antibacteriano, e, agente terapêutico para doença infecciosa

Info

Publication number
BRPI0821855A2
BRPI0821855A2 BRPI0821855-2A BRPI0821855A BRPI0821855A2 BR PI0821855 A2 BRPI0821855 A2 BR PI0821855A2 BR PI0821855 A BRPI0821855 A BR PI0821855A BR PI0821855 A2 BRPI0821855 A2 BR PI0821855A2
Authority
BR
Brazil
Prior art keywords
agent
compound
infectious disease
bacterial dna
dna gyrase
Prior art date
Application number
BRPI0821855-2A
Other languages
English (en)
Inventor
Tsuyoshi Soneda
Hiroshi Takeshita
Yoshiko Kagoshima
Yuko Yamamoto
Takafumi Hosokawa
Toshiyuki Konosu
Nobuhisa Masuda
Takuya Uchida
Issei Achiwa
Junichi Kuroyanagi
Tetsunori Fujisawa
Aki Yokomizo
Tetsuji Noguchi
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BRPI0821855A2 publication Critical patent/BRPI0821855A2/pt
Publication of BRPI0821855B1 publication Critical patent/BRPI0821855B1/pt
Publication of BRPI0821855B8 publication Critical patent/BRPI0821855B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0821855A 2007-12-27 2008-12-26 composto, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável do mesmo BRPI0821855B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007337693 2007-12-27
JP2007-337693 2007-12-27
PCT/JP2008/073686 WO2009084614A1 (ja) 2007-12-27 2008-12-26 イミダゾールカルボニル化合物

Publications (3)

Publication Number Publication Date
BRPI0821855A2 true BRPI0821855A2 (pt) 2015-06-16
BRPI0821855B1 BRPI0821855B1 (pt) 2019-08-27
BRPI0821855B8 BRPI0821855B8 (pt) 2021-05-25

Family

ID=40824327

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821855A BRPI0821855B8 (pt) 2007-12-27 2008-12-26 composto, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável do mesmo

Country Status (11)

Country Link
US (2) US8536197B2 (pt)
EP (1) EP2226322B1 (pt)
JP (2) JP5586234B2 (pt)
KR (1) KR101578954B1 (pt)
CN (1) CN101959882B (pt)
BR (1) BRPI0821855B8 (pt)
CA (1) CA2710959C (pt)
ES (1) ES2535085T3 (pt)
HK (1) HK1147259A1 (pt)
TW (1) TWI498115B (pt)
WO (1) WO2009084614A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI498115B (zh) 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
GB2498080A (en) * 2011-12-21 2013-07-03 Redx Pharma Ltd Derivatives of oseltamivir
US9034874B2 (en) * 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
CN104016925B (zh) * 2014-06-17 2016-03-30 遵义医学院 4-烷基咪唑-2-羧酸的合成方法
CN104059020B (zh) * 2014-06-27 2016-08-31 湖南海利常德农药化工有限公司 1-芳基-5-羟基吡唑的制备方法
KR20180022826A (ko) 2015-07-02 2018-03-06 얀센 사이언시즈 아일랜드 유씨 항균 화합물
CN108137574B (zh) * 2015-09-30 2021-12-28 第一三共株式会社 羟烷基噻二唑衍生物
WO2017216281A1 (en) 2016-06-16 2017-12-21 Janssen Sciences Ireland Uc Heterocyclic compounds as antibacterials
CN110831630A (zh) 2017-03-01 2020-02-21 爱尔兰詹森科学公司 组合疗法
JP2020511457A (ja) * 2017-03-14 2020-04-16 第一三共株式会社 ヒドロキシアルキルチアジアゾール誘導体のｎ−ホスホノキシメチルプロドラッグ
JPWO2018174288A1 (ja) 2017-03-24 2020-01-23 大正製薬株式会社 ２（１ｈ）−キノリノン誘導体
US20210323957A1 (en) 2018-09-03 2021-10-21 Univerza V Ljubljani New class of dna gyrase and/or topoisomerase iv inhibitors with activity against gram-positive and gram-negative bacteria
CN113045564A (zh) * 2019-12-27 2021-06-29 上海天慈国际药业有限公司 一种阿培利司的制备方法
CN111592495A (zh) * 2020-07-06 2020-08-28 上海启讯医药科技有限公司 一种2-正丁基-4-氯-5甲酰基咪唑的制备方法
CN115989225A (zh) * 2020-08-31 2023-04-18 豪夫迈·罗氏有限公司 作为抗菌药物的咪唑-吡唑衍生物
CN115989227A (zh) * 2020-09-01 2023-04-18 豪夫迈·罗氏有限公司 具有抗菌性的咪唑-吡唑衍生物
WO2022129327A1 (en) 2020-12-17 2022-06-23 Univerza V Ljubljani New n-phenylpyrrolamide inhibitors of dna gyrase and topoisomerase iv with antibacterial activity
CN114436991A (zh) * 2021-12-25 2022-05-06 上海泰坦科技股份有限公司 一种2-氨基噻唑类化合物的合成方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2241677A (en) * 1976-03-12 1978-08-24 Bayer Ag 4,5-dichloroimidazole-2-carboxylic acid derivatives
US4602095A (en) * 1983-12-29 1986-07-22 General Foods Corporation 3-hydroxy-4-alkyloxyphenyl heterocyclic aromatic carboxylates
GB8531665D0 (en) * 1985-12-23 1986-02-05 Wyeth John & Brother Ltd Indole derivatives
US5082847A (en) * 1990-07-18 1992-01-21 Syntex (U.S.A.) Inc. Carbostyril compounds connected via an oxyalkyl group with a piperidine ring and having pharmaceutical utility
IL101851A (en) * 1991-06-13 1996-05-14 Janssen Pharmaceutica Nv History 01 -) 4 - Pipridinyl - and Pipridinylidene (- Imidazo] A-1,2 [Pirolo, Thiano or Purano (] 3,2 [Azpin, their preparation and pharmaceutical preparations containing them and composition
EP0585500A1 (en) * 1992-09-04 1994-03-09 Merrell Dow Pharmaceuticals Inc. Diaryl piperazineacetamides as antimuscarinic agents
US5318975A (en) * 1993-02-16 1994-06-07 Berlex Laboratories, Inc. 5-pyrimdineamine derivatives
TW593317B (en) * 1993-06-21 2004-06-21 Janssen Pharmaceutica Nv Positive cardiac inotropic and lusitropic pyrroloquinolinone derivatives
WO1999011642A1 (en) * 1997-08-29 1999-03-11 Zeneca Limited Aminometyl oxooxazolidinyl benzene derivatives
WO1999045009A1 (en) * 1998-03-04 1999-09-10 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
AR030537A1 (es) * 1999-11-05 2003-08-27 Abbott Lab Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos
JP2004537526A (ja) * 2001-06-12 2004-12-16 メルク　エンド　カムパニー　インコーポレーテッド 片頭痛の治療又は予防用ｎｒ２ｂ受容体拮抗薬
CA2513416A1 (en) * 2002-08-22 2004-03-04 Orchid Chemicals & Pharmaceuticals Ltd. Novel antibacterial agents
WO2004041795A1 (en) * 2002-10-30 2004-05-21 Guilford Pharmaceuticals Inc. Novel inhibitors of dipeptidyl peptidase iv
EP1613613B1 (en) * 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
WO2005003087A2 (en) * 2003-07-01 2005-01-13 Orchid Chemicals And Pharmaceuticals Ltd. Oxazole derivatives as antibacterial agents
GB0317516D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
GB0321509D0 (en) * 2003-09-13 2003-10-15 Astrazeneca Ab Chemical compounds
TW200526626A (en) * 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
WO2005030128A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
CA2565018A1 (en) * 2004-04-28 2005-11-10 Takeda Pharmaceutical Company Limited Fused quinoline derivative and use thereof
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
US7705042B2 (en) * 2004-10-22 2010-04-27 Janssen Pharmaceutica Nv Class of arylamide compounds useful as inhibitors of c-fms kinase
ES2611604T3 (es) * 2004-10-22 2017-05-09 Janssen Pharmaceutica Nv Inhibidores de la c fms quinasa
DK1831159T3 (da) 2004-12-21 2010-03-22 Hoffmann La Roche Tetralin og indanderivater samt anvendelser deraf
CN101163697A (zh) 2005-02-18 2008-04-16 阿斯利康(瑞典)有限公司 作为dna促旋酶和拓扑异构酶抑制剂的吡咯衍生物
WO2006087548A2 (en) 2005-02-18 2006-08-24 Astrazeneca Ab Pyrrole derivatives as dna gyrase and topoisomerase inhibitors
UA94901C2 (ru) * 2005-02-18 2011-06-25 Астразенека Аб Антибактериальные производные пиперидина
GB0503646D0 (en) * 2005-02-22 2005-03-30 Novartis Ag Organic compounds
CN101171247A (zh) 2005-03-04 2008-04-30 阿斯利康(瑞典)有限公司 作为dna促旋酶和拓扑异构酶抑制剂的吡咯衍生物
US20090253671A1 (en) 2005-03-04 2009-10-08 Astrazeneca Ab Tricyclic derivatives of azetidine and pyrrole with antibacterial activity
NZ561029A (en) * 2005-03-14 2011-03-31 High Point Pharmaceuticals Llc Benzazole dervatives, compositions, and method of use as beta-secretase inhibitors
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
JP2009501199A (ja) * 2005-07-12 2009-01-15 グラクソ グループ リミテッド Ｇｐｒ３８アゴニストとしてのピペラジンヘテロアリール誘導体
JP2009520785A (ja) 2005-12-23 2009-05-28 アストラゼネカ アクチボラグ 抗菌性のピロロピリジン、ピロロピリミジン、及びピロロアゼピン
US7651687B2 (en) * 2006-03-13 2010-01-26 Osi Pharmaceuticals, Inc. Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
EP2004626A4 (en) * 2006-03-23 2010-10-27 Synta Pharmaceuticals Corp BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS
EP2076513A1 (en) * 2006-10-20 2009-07-08 Irm Llc Compositions and methods for modulating c-kit and pdgfr receptors
CA2672815A1 (en) 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives for use in treating abnormal cell growth
TWI498115B (zh) 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物

Also Published As

Publication number Publication date
TWI498115B (zh) 2015-09-01
JP2014196369A (ja) 2014-10-16
US8927588B2 (en) 2015-01-06
EP2226322B1 (en) 2015-01-21
KR20100098657A (ko) 2010-09-08
JP5586234B2 (ja) 2014-09-10
BRPI0821855B1 (pt) 2019-08-27
KR101578954B1 (ko) 2015-12-18
JPWO2009084614A1 (ja) 2011-05-19
CN101959882A (zh) 2011-01-26
ES2535085T3 (es) 2015-05-05
CA2710959A1 (en) 2009-07-09
US20100311966A1 (en) 2010-12-09
EP2226322A4 (en) 2011-06-08
WO2009084614A1 (ja) 2009-07-09
JP5798221B2 (ja) 2015-10-21
BRPI0821855B8 (pt) 2021-05-25
HK1147259A1 (en) 2011-08-05
US8536197B2 (en) 2013-09-17
CN101959882B (zh) 2013-09-11
US20140073622A1 (en) 2014-03-13
TW200932221A (en) 2009-08-01
EP2226322A1 (en) 2010-09-08
CA2710959C (en) 2013-10-01

Similar Documents

Publication Publication Date Title
BRPI0821855A2 (pt) Composto, agente farmacêutico, uso de um composto inibidor de dna girase bacteriana, agente antibacteriano, e, agente terapêutico para doença infecciosa
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
BRPI0720637A2 (pt) Composto ou um sal farmaceuticamente aceitável, uma forma estereoisomérica, tautomérica ou polimórfica do mesmo, métodos para o tratamento de um hospedeiro e de tratamento de infecção, composição farmacêutica, e, uso do composto
BRPI0809656A2 (pt) Atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica
BRPI0815385A2 (pt) Produtos medicinais farmaceuticamente revestidos melhorados, fabricação e uso dos mesmos
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
IL228017A0 (en) Quinazolinone derivatives donated at position 5 as anti-cancer agents
BRPI0807544A2 (pt) Sólido farmacêutico e dose de vacina
BRPI0818193A2 (pt) composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0917458A2 (pt) composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
BRPI0820665A2 (pt) compostos de peptidil nitrilas, processos para fabricação dos mesmos, composição farmacêutica, combinação e uso de ditos compostos
CL2007003645A1 (es) Compuestos parasiticidas derivados de aril-pirazoles sustituidos; compuestos intermediarios; composicion farmaceutica; y uso para tratar una infeccion parasitaria.
CL2008001002A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0811865A2 (pt) Derivados heterocíclicos pirrolo-nitrogenados, a preparação e o uso farmacêutico dos mesmos
BRPI0814957A2 (pt) Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.
BRPI0907977A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
CL2008001003A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0907974A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0915120A2 (pt) composto derivado de oxima, uso do referido composto e composição farmacêutica
BRPI0907892A2 (pt) Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2535 DE 06/08/2019,QUANTO AO ITEM (71) NOME DO DEPOSITANTE.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2755 DE 24-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.